Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $18.43 Average Price Target from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned a consensus recommendation of “Hold” from the twenty-four ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $18.4348.

NTLA has been the topic of several recent research reports. William Blair lowered Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 27th. Citizens Jmp reduced their target price on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. JMP Securities lowered their price target on Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a research note on Tuesday, October 28th. HC Wainwright cut their price target on shares of Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Finally, Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, October 30th.

Insider Activity

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the completion of the sale, the chief accounting officer owned 55,266 shares in the company, valued at $960,523.08. This represents a 3.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Intellia Therapeutics by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 11,044,820 shares of the company’s stock valued at $190,744,000 after purchasing an additional 192,651 shares in the last quarter. Contrarius Group Holdings Ltd raised its holdings in Intellia Therapeutics by 279.4% during the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after buying an additional 4,337,428 shares during the period. Baker BROS. Advisors LP lifted its stake in Intellia Therapeutics by 2.7% in the third quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after buying an additional 71,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Intellia Therapeutics by 5.1% in the second quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company’s stock valued at $24,449,000 after buying an additional 126,049 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Intellia Therapeutics by 7.6% in the third quarter. Two Sigma Investments LP now owns 2,449,607 shares of the company’s stock valued at $42,305,000 after buying an additional 173,033 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $9.58 on Friday. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -2.24 and a beta of 2.13. The company has a 50 day moving average of $11.79 and a 200-day moving average of $12.63. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. During the same period in the prior year, the business posted ($1.34) earnings per share. Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. Equities research analysts anticipate that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.